Janus Henderson Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.98B Sell
4,347,394
-94,583
-2% -$95.9M 1.9% 7
2025
Q4
$4.75B Sell
4,441,977
-85,897
-2% -$82.1M 2.13% 7
2025
Q3
$3.45B Buy
4,527,874
+143,012
+3% +$106M 1.58% 10
2025
Q2
$3.42B Sell
4,384,862
-147,750
-3% -$115M 1.68% 9
2025
Q1
$3.73B Buy
4,532,612
+48,069
+1% +$40M 2.04% 7
2024
Q4
$3.46B Buy
4,484,543
+449,460
+11% +$372M 1.76% 9
2024
Q3
$3.57B Sell
4,035,083
-106,163
-3% -$95.4M 1.83% 7
2024
Q2
$3.75B Buy
4,141,246
+565,562
+16% +$452M 2.01% 7
2024
Q1
$2.78B Buy
3,575,684
+243,729
+7% +$173M 1.52% 8
2023
Q4
$1.94B Buy
3,331,955
+915,324
+38% +$534M 1.16% 9
2023
Q3
$1.3B Sell
2,416,631
-90,379
-4% -$46.6M 0.85% 13
2023
Q2
$1.18B Sell
2,507,010
-834,119
-25% -$350M 0.73% 21
2023
Q1
$1.15B Sell
3,341,129
-299,541
-8% -$101M 0.76% 20
2022
Q4
$1.33B Sell
3,640,670
-3,800,494
-51% -$1.35B 0.95% 14
2022
Q3
$2.41B Buy
7,441,164
+3,508,509
+89% +$1.11B 0.9% 14
2022
Q2
$1.28B Sell
3,932,655
-1,147,952
-23% -$345M 0.88% 12
2022
Q1
$1.45B Sell
5,080,607
-379,771
-7% -$97.7M 0.7% 17
2021
Q4
$1.51B Buy
5,460,378
+680,641
+14% +$173M 0.63% 22
2021
Q3
$1.1B Sell
4,779,737
-92,003
-2% -$22.7M 0.48% 36
2021
Q2
$1.12B Sell
4,871,740
-140,005
-3% -$28.1M 0.48% 32
2021
Q1
$936M Sell
5,011,745
-1,113,176
-18% -$218M 0.43% 49
2020
Q4
$1.03B Buy
6,124,921
+302,296
+5% +$45.1M 0.48% 36
2020
Q3
$862M Buy
5,822,625
+258,330
+5% +$40M 0.45% 42
2020
Q2
$914M Buy
5,564,295
+786,253
+16% +$121M 0.51% 37
2020
Q1
$663M Sell
4,778,042
-486,130
-9% -$66.8M 0.46% 44
2019
Q4
$692M Sell
5,264,172
-932,458
-15% -$108M 0.35% 66
2019
Q3
$693M Sell
6,196,630
-410,806
-6% -$45.7M 0.38% 65
2019
Q2
$732M Sell
6,607,436
-2,217,899
-25% -$261M 0.4% 56
2019
Q1
$1.15B Sell
8,825,335
-124,561
-1% -$15.1M 0.63% 20
2018
Q4
$1.04B Sell
8,949,896
-213,599
-2% -$23.9M 0.66% 16
2018
Q3
$983M Sell
9,163,495
-845,273
-8% -$84.5M 0.53% 27
2018
Q2
$854M Buy
10,008,768
+700,582
+8% +$57.5M 0.49% 31
2018
Q1
$720M Sell
9,308,186
-708,562
-7% -$57M 0.42% 46
2017
Q4
$846M Sell
10,016,748
-840,445
-8% -$71.5M 0.51% 33
2017
Q3
$929M Buy
10,857,193
+1,503,918
+16% +$123M 0.6% 22
2017
Q2
$770M Buy
9,353,275
+9,223,251
+7,093% +$752M 0.52% 28
2017
Q1
$10.9M Sell
130,024
-940
-0.7% -$75.3K 0.08% 268
2016
Q4
$9.64M Buy
130,964
+14,262
+12% +$1.06M 0.07% 284
2016
Q3
$9.36M Buy
116,702
+20,913
+22% +$1.67M 0.07% 282
2016
Q2
$7.54M Buy
95,789
+55,304
+137% +$4.16M 0.06% 285
2016
Q1
$2.92M Sell
40,485
-116,088
-74% -$8.78M 0.02% 426
2015
Q4
$13.2M Buy
156,573
+30,004
+24% +$2.49M 0.11% 216
2015
Q3
$10.6M Buy
126,569
+86,084
+213% +$7.27M 0.09% 239
2015
Q2
$3.38M Sell
40,485
-9,414
-19% -$717K 0.03% 411
2015
Q1
$3.63M Hold
49,899
0.03% 418
2014
Q4
$3.44M Sell
49,899
-8,203
-14% -$554K 0.02% 423
2014
Q3
$3.77M Sell
58,102
-7,130
-11% -$451K 0.04% 319
2014
Q2
$4.06M Hold
65,232
0.04% 308
2014
Q1
$3.84M Buy
65,232
+29,367
+82% +$1.64M 0.04% 319
2013
Q4
$1.83M Buy
35,865
+8,400
+31% +$421K 0.02% 423
2013
Q3
$1.38M Buy
27,465
+2,265
+9% +$119K 0.02% 466
2013
Q2
$1.26M Buy
+25,200
New +$1.37M 0.01% 468

Other funds holding LLY

Janus Henderson Group's LLY Position: Q1 2026 in Review

Janus Henderson Group reduced its Eli Lilly (LLY) stake by 2.1% in Q1 2026, selling an estimated $95.9M and leaving 4,347,394 shares worth $3.98B. The position accounts for 1.9% of the portfolio, ranked #7.

Janus Henderson Group first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.75B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Janus Henderson Group held 4,347,394 shares of Eli Lilly worth $3.98B as of Q1 2026.
  • Janus Henderson Group sold 94,583 Eli Lilly shares in Q1 2026, an estimated $95.9M.
  • Eli Lilly made up 1.9% of Janus Henderson Group's portfolio in Q1 2026, its #7 holding.
  • Janus Henderson Group first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Janus Henderson Group's Eli Lilly position peaked at $4.75B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.